

Akrivia Biosciences secures pre-seed funding to advance precision cancer diagnostics

17 March 2025 | News

Funding will be utilised for the formation of an internal R&D team



Akrivia Biosciences, a Mumbai-based deeptech startup in oncology precision diagnostics, has closed its pre-seed funding through Compulsory Convertible Debentures (CCDs) from JITO Incubation and Innovation Foundation (JIIF) and Rebalance Angels.

This funding will be utilised for Proof of Concept trials, the formation of an internal R&D team, and scientific publications that support its breakthrough innovations in cancer treatment.

Akrivia Biosciences is revolutionising cancer diagnostics with its next-generation molecular subtyping tests. By leveraging a multi-omics approach, Akrivia is transforming cancer treatment by providing oncologists with precise and comprehensive data to guide personalized therapy. This innovation is reducing overtreatment, improving patient outcomes, and marking a paradigm shift in how cancer is diagnosed and treated.

“The world is recognising the significance of precision medicine, which aims to provide the right cancer treatment to the right patient at the right time based on their unique molecular makeup. Akrivia Biosciences is bringing a multi-omics-based next-generation precision treatment solution that can transform cancer treatment strategies from a one-size-fits-all approach to precision medicine in its truest sense,” said Sagar Gosalia, COO of JIIF.

He further added “Our investment in Akrivia Biosciences aligns with our commitment to backing deeptech ventures that address critical healthcare challenges. Akrivia’s work in oncology precision diagnostics has the potential to redefine cancer treatment by enabling targeted, effective, and personalized therapies,”

Akrivia was founded based on a breakthrough discovery made by Dr Amit Gupta while analysing cancer genomic data. His research has led to a deeper understanding of tumour biology and its impact on disease progression and treatment response. This knowledge has been validated through studies involving approximately 8,000 cancer patients over four years.

“Our tests are designed to go beyond conventional genetic panels. They provide oncologists with actionable insights, including long-term risk assessment of cancer recurrence and selection of the most effective targeted therapies for individual

patients,” said Dr Amit Gupta, Co-founder of Akrivia Biosciences.